INBX - Company ID 0001739614
The table below shows Inhibrx, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|
| Operating cash flow | -$63.05M | -$39.94M | -$26.94M | -$21.65M | -$7.39M |
| Capital expenditure | $1.12M | $23.00K | $117.00K | $14.00K | $91.00K |
| Investing cash flow | -$1.12M | -$23.00K | -$117.00K | -$14.00K | -$91.00K |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - |
Inhibrx, Inc. reported operating cash flow of -$193.31M for fiscal year 2023. That is down 67.7% from -$115.30M in fiscal 2022. Over the 5 fiscal years shown, operating cash flow declined from -$32.08M (FY 2019) to -$193.31M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| - |
| Financing cash flow | $38.73M | $356.00K | $39.22M | $988.00K | -$3.63M |